share_log

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation

バイオテクノロジーの毎日のパルス:Pfizer-BioNTechのCOVID-19ブースターが5〜11歳の子供向けにまもなく登場、遺伝性障害のためのジーンセラピーをライセンス供与するUltragenyx、AmpioのAP-013トライアルが独立調査の対象に

Benzinga Real-time News ·  2022/05/17 09:09

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT

The FDA is expected to authorize a booster shot ofPfizer Inc(NYSE:PFE)/BioNTech SE's(NASDAQ:BNTX) COVID-19 vaccine for children ages 5 to 11, likely Tuesday, the New York Times reported, citing people familiar with the matter.

It is unclear how much demand there is for the third dose in the age group. According to the U.S. Centers for Disease Control and Prevention, just 28.8% of children ages...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする